Featured Research

from universities, journals, and other organizations

High-dose, short-course radiation for prostate cancer does not increase side effects, study finds

Date:
December 7, 2010
Source:
Fox Chase Cancer Center
Summary:
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

In the case of short-course, high-dose (hypofractionated) radiation therapy, the answer is no, according research at Fox Chase Cancer Center led by Aruna Turaka, M.D., radiation oncologist at Fox Chase. Turaka is presenting the results on Nov. 2nd at the annual meeting of the American Society for Radiation Oncology.

Turaka and colleagues compared two groups of prostate cancer patients treated with intensity-modulated radiation therapy (IMRT), a technique that uses multiple beams of varying intensities to precisely radiate tumors while minimizing exposure to healthy, adjacent tissues. One group received conventional IMRT; the other group was treated with hypofractionated IMRT, which delivers a higher total dose of radiation in fewer sessions.

The patients -- a total of 307 men randomly assigned to one or the other treatment group -- were given quality of life assessments at the beginning of treatment and six, 12, and 24 months later. They were also evaluated at the same timepoints for genitourinary and gastrointestinal problems.

"We found no significant differences between the two groups," says Turaka. "Hypofractionated IMRT not only decreases the treatment duration -- 26 days compared to 38 days for conventional IMRT -- but it also allows us to deliver a higher total dosage. Our results tell us that we can achieve these higher dosages with no change in side effect profile or quality of life."

Longer follow-up is needed to draw conclusions about the relative efficacy of regular and hypofractionated IMRT in treating prostate cancer, Turaka says.

In addition to Turaka, the paper's authors are biostatistics instructor Fang Zhu, Ph.D; radiation oncologist Mark Buyyounouski; M.D.; and Eric Horwitz, M.D., the Gerald E. Hanks Chair in Radiation Oncology, all of Fox Chase Cancer Center; Deborah Watkins-Bruner, Ph.D., R.N., the Independence Professor in Nursing Education at the University of Pennsylvania School of Nursing; Andre Konski, M.D., M.B.A., chair of radiation oncology at Wayne State University School of Medicine; and Alan Pollack, M.D., Ph.D., professor and chair of radiation oncology at University of Miami School of Medicine.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "High-dose, short-course radiation for prostate cancer does not increase side effects, study finds." ScienceDaily. ScienceDaily, 7 December 2010. <www.sciencedaily.com/releases/2010/11/101101093608.htm>.
Fox Chase Cancer Center. (2010, December 7). High-dose, short-course radiation for prostate cancer does not increase side effects, study finds. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2010/11/101101093608.htm
Fox Chase Cancer Center. "High-dose, short-course radiation for prostate cancer does not increase side effects, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/11/101101093608.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins